SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as discussions revolve around a boosted price target from an analyst, potentially signaling further upward momentum, while others point to declining sales figures and expiring EV subsidies, suggesting a possible downturn. The community is actively debating Tesla's financial health, delivery reports, and Elon Musk's strategic moves amid evolving competition in the EV sector. Broader market factors and technical levels are also being closely watched for potential directional shifts.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent listing on Bifinance and anticipates upcoming utility releases. Active community members highlight the coin's resilience and ongoing development efforts, emphasizing a grind mentality. Discussions also mention a watcher count milestone that could trigger a token burn.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid reports of potential investments or partnerships with TSMC and Apple, fueling speculation about its comeback in the semiconductor market. The community is actively discussing the implications of these developments, viewing them as a potential catalyst for growth. Broader discussions involve the company's role in the evolving tech ecosystem and government support for domestic chip manufacturing.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending due to a newly announced offering and a multi-billion dollar AI compute deal, sparking mixed reactions in the community. While some investors express concern over potential dilution from the offering, others view the deal with Google-backed Fluidstack as a major catalyst for growth in the AI data center space. Discussions also involve comparing $CIFR to peers like $IREN and analyzing potential price movements based on technical indicators and market sentiment.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

Iris Energy (IREN) is trending as analysts boost price targets, citing the company's shift toward AI cloud services and strong execution. Community members are actively debating the stock's valuation and potential for further growth, with some pointing to the company's power capacity and AI infrastructure buildout. Recent discussions also highlight overnight price drops possibly due to market manipulation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to a mix of factors, including positive trial data for their Alzheimer's treatment and GLP-1 pill, potentially impacting its competition with Novo Nordisk. Community discussions revolve around the implications of new U.S. manufacturing plants in light of potential tariffs, as well as debate over the efficacy and side effects of different weight loss drugs in the sector.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as the community compares it to $PEPE, suggesting it could be the next big meme coin, particularly within the Solana ecosystem. Traders are highlighting bullish chart patterns and increased buying activity, with many emphasizing the ease of access through Phantom Wallet. The conversation is centered around the potential for a significant breakout and 'moon mission'.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The 'crow with knife' ($CAW.X) meme coin is gaining attention, with community members emphasizing its strong community and organic growth. Discussions highlight its presence across multiple chains like $SOL.X, $CRO.X, and $ETH.X, with a built-in burn mechanism that reduces supply over time.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQQF is trending due to anticipation surrounding its upcoming Nasdaq uplisting, with the community discussing potential impacts on price and institutional investment. Some traders are expressing concerns about possible dilution following the uplist, drawing parallels to a similar situation with DEFT. Bullish sentiment remains, driven by the company's focus on quantum-safe cryptography and endorsements of their QSSN technology.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI.X is trending as community members express strong conviction and excitement, using the term "WAGMI" (We Are All Gonna Make It) to foster a sense of unity. Discussions revolve around the token's potential for significant growth, its strong community, and its role within the broader meme coin cycle, particularly on the Solana blockchain and Pump.fun platform. Some users are highlighting the token's branding and positive messaging, suggesting it could be the next breakout narrative in the meme coin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solid Biosciences drew heightened retail chatter on Tuesday following&nbsp;approvals for human trials by U.S. and Canadian regulators to test its gene therapy,&nbsp; SGT-501, for a life-threatening heart rhythm condition&nbsp;called catecholaminergic polymorphic ventricular tachycardia (CPVT).This inherited disorder commonly affects children and young adults who experience dangerous arrhythmias when stressed or exercising with no existing FDA-approved treatments available in the U.S.Shares of the Charlestown, Massachusetts-based company, which ended Tuesday more than 6% higher, gained over 4% in after-hours trading following the announcement.Solid Biosciences&nbsp;plans to launch a Phase 1b trial later this year to determine the safety and effectiveness of the therapy.&nbsp;SGT-501 holds Orphan Drug and Rare Pediatric Disease designations in the U.S. that offer development and commercialization incentives, including extended exclusivity, and accelerated reviews when the drug candidate enters an approval application stage.The treatment employs a viral tool to introduce a functional CASQ2 gene into cardiac muscle cells.&nbsp;The CASQ2 gene&nbsp;encodes a protein essential for heart cells to maintain&nbsp;regular calcium release and uptake during each heartbeat.&nbsp;The genetic changes found in CPVT patients result in&nbsp;a disruption of&nbsp;calcium flow, which triggers abnormal heart rhythms.The company is also advancing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD).&nbsp;Last week, Citi initiated coverage on Solid with a&nbsp;‘Buy’ rating and a $14 price target, citing favorable risk-reward dynamics and a cleaner safety profile for SGT-003 compared to Sarepta’s Elevidys, which has been&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-dmd-gene-therapy-trial-after-second-death-retail-traders-brush-off-risk/chlnJFARRbY">under scrutiny</a> following reports of liver-related fatalities.H.C. Wainwright also maintained a ‘Buy’ rating on Solid, calling SGT-003 the most promising DMD gene therapy currently in development or on the market.On Stocktwits, retail sentiment for Solid was ‘extremely bullish’ amid ‘extremely high’ message volume.One user reflected on a missed opportunity, noting they “hesitated to add more” at $2.40 and now “regret it,” saying they should have purchased at least 800 shares.&nbsp;<stembedurl>https://stocktwits.com/Rolex53/message/620276017</stembedurl>Another user questioned whether the post-news spike to $5.80 was the peak, acknowledging the announcement as “critical confirmation of our product pipeline,” but also cautioning that it’s not the same as fast-tracking or trial success.<stembedurl>https://stocktwits.com/The_Red_Fox/message/620258395</stembedurl><a href="https://stocktwits.com/symbol/SLDB">SLDB’s stock</a> has risen 34.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Solid Biosciences (SLDB) got approvals for human trials by U.S. and Canadian regulators to test its gene therapy,  SGT-501/ Photo credit: Getty Images

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

The company plans to begin a Phase 1b trial of SGT-501 later this year, targeting CPVT, a rare and potentially fatal arrhythmia in children and young adults with no current FDA-approved therapies.

Equity

Stock market today: S&P 500 in Q1 loss despite jump; 'liberation day' tariffs loom

Investing.com-- The S&P 500 closed higher Monday, as a dip to six-month lows drew support, but the index ended the first quarter lower just days ahead of President Donald Trump’s April 2 "liberation day" deadline to impose more reciprocal tariffs. 

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended gains in after-hours trading. On Stocktwits, the ticker's retail followers jumped by 11%.Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.Interim 90-day biopsy data from the Phase 1/2 trial showed:<ul style="list-style-type:square;"><li>110% average microdystrophin expression (via western blot) in the first three participants</li><li>Improvements in multiple biomarkers, indicating better muscle health and resilience</li><li>SGT-003 was well-tolerated, with no serious adverse events or signs of major complications like thrombotic microangiopathy</li></ul>&nbsp;Adverse events included nausea, vomiting, fever, and transient platelet declines—which the company said were typical for adeno-associated virus gene therapy—but none required additional immunomodulatory treatments.Following the data, according to The Fly, Chardan raised its price target on Solid Biosciences to $16 from $15, implying more than a 200% upside from Tuesday’s close.&nbsp;The research firm also increased the therapy's probability of success to 48%, citing strong early efficacy signals and manageable safety.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume skyrocketing over 5,500% to the highest level in three months.One user commented that the "real appreciation" for the stock will start "once the day traders leave."<stembedurl>https://stocktwits.com/pharmd2828/message/604696890</stembedurl>Another suggested the stock could "double in no time" based on "pretty compelling data."<stembedurl>https://stocktwits.com/iSmith/message/604695964</stembedurl>Early results from a Stocktwits poll showed 49% of respondents believe SGT-003 could be a blockbuster, while 20% think it's "just hype."<figure class="image"><img style="aspect-ratio:1314/1062;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLDB_poll_and_sentiment_meter_on_Feb_18_7c2cbe8810.png" alt="SLDB poll and sentiment meter on Feb 18.png" width="1314" height="1062"><figcaption>SLDB poll and sentiment meter on Feb 18 | source: Stocktwits</figcaption></figure>Separately, Solid Biosciences announced a $200 million underwritten offering, pricing 35.7 million common shares at $4.03 per share and 13.9 million pre-funded warrants at $4.029 apiece. The offering is set to close on Wednesday.According to Koyfin, short interest on SLDB has climbed from 4.4% at the start of the year to 6.6%.<a href="https://stocktwits.com/symbol/SSRM">Solid Biosciences stock</a> is now up over 31% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...

Solid Biosciences' SGT-003 receives rare pediatric disease designation

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
The post Solid Biosciences' SGT-003...

Solid Biosciences (SLDB, $12.44) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that SLDB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Solid Biosciences (SLDB, $12.44) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2024

This is a Bearish indicator signaling SLDB's price could decline from here. Traders may explore shorting the stock or put options...

Solid Biosciences receives Rae Pediatric Disease designation for SGT-003

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 CHARLESTOWN, Mass...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

SLDB
Solid Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLDB News

SLDB Solid Biosciences Inc